13F

Investor

22NW, LP

CIK 0001694297 · filed 2026-02-13 · SEC filing

13F book

$237.6M

Positions

20

Largest name

35.7%

Anebulo Pharmaceuticals, Inc. · ANEB

Est. mark

Need a prior quarter to estimate
NameTickerSharesValueWeightEst. markChange
Anebulo Pharmaceuticals, Inc.ANEB15.5M$84.8M35.7%Held
Foster L B CoFSTR1.19M$32.1M13.5%Held
Lifecore Biomedical Inc1.25K$23M9.7%Held
Nektar TherapeuticsNKTR331.1K$14M5.9%Held
REGENXBIO Inc.RGNX923.7K$13.3M5.6%Held
Mineralys Therapeutics, Inc.MLYS358.3K$13M5.5%Held
Stoneridge IncSRI2.19M$12.7M5.3%Held
Mayville Engr Co Inc414.3K$7.76M3.3%Held
Culp IncCULP1.86M$6.62M2.8%Held
Phenixfin Corp117.9K$5.21M2.2%Held
Meiragtx Hldgs Plc586.5K$4.66M2.0%Held
Core Molding Technologies In222.7K$4.47M1.9%Held
Insperity, Inc.NSP96.3K$3.73M1.6%Held
Unifi IncUFI852.5K$2.98M1.3%Held
Farmer Bros Co1.96M$2.86M1.2%Held
Team IncTISI170.2K$2.4M1.0%Held
Rezolute, Inc.RZLT820.7K$1.94M0.8%Held
Eledon Pharmaceuticals, Inc.ELDN636.4K$960.9K0.4%Held
Strata Skin Sciences Inc537K$676.6K0.3%Held
Psychemedics Corporation Cmn276K$441.7K0.2%Held

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.